Yintai Medical Expands Cardiovascular Portfolio with Dual Acquisitions of Valgen and Pulin

　　【Pharmaceutical Net Corporate News] On June 25, INT Medical announced a disclosable transaction, proposing to conditionally acquire approximately 0.79% of the equity interest in Valgen Holding Corporation. According to the announcement, the company intends to purchase from the seller 119,545 shares of Series B Preferred Stock (the Further Sale Shares) of the target company, representing approximately 0.79% of the target company’s total issued share capital, for a total consideration of USD 10 million.
 

In May 2026, INT Medical issued an announcement stating that the company had entered into a share transfer agreement with relevant sellers to acquire equity in Valgen Holding Corporation. The total number of shares purchased amounted to 3.4944 million, representing 23.18% of the total issued share capital of Valgen Holding Corporation, with a total consideration of USD 108 million.
 

INT Medical’s acquisition of the target company’s equity aims to provide the Company with an opportunity to supplement its product pipeline in the field of structural heart disease, achieve broader product coverage in this area, and enhance the Group’s overall competitiveness in the cardiovascular intervention sector. It is understood that the target company holds 100% equity interest in Valgen Medtech, which is primarily engaged in the research, development, production, and sales of interventional treatment technologies and products for atrioventricular valve diseases, particularly mitral and tricuspid valve interventions. Currently, several of its products have been included in the National Medical Products Administration’s Special Examination Procedure for Innovative Medical Devices, among which DragonFly® is the first domestically produced transcatheter mitral valve product approved in China.
 

On the same day, INT Medical also announced that it plans to acquire a total of 35% equity interest in Pulin Medical. According to the valuation report issued by Zhuoli’ao (Shanghai) Asset Appraisal Firm (General Partnership), an independent valuer, using the income approach (discounted cash flow method), the assessed value of all shareholders’ equity in Pulin Medical was RMB 89.3869 million as of the benchmark date of March 31, 2026.
 

Upon completion of this acquisition, INT Medical’s shareholding in Pulin Medical will increase from 65% to 100%, achieving full ownership. Public information indicates that Pulin Medical is an important subsidiary of the company, primarily responsible for the promotion and sales of the group’s medical devices within China. This acquisition will help enhance the efficiency of the group’s overall operational control and business synergy, thereby improving the company’s overall sustainable development.
 

Overall, INT Medical’s acquisition of Valgen (Dejin) aims to bolster its high-growth structural heart valve pipeline and establish a comprehensive cardiovascular portfolio, while the acquisition of Pulin Medical is intended to strengthen its nationwide commercialization channels and address challenges in promoting multiple new products for hospital adoption. In the future, the company is expected to continue seeking high-quality assets that complement its cardiovascular intervention landscape.
 

In fact, in January 2026, INT Medical raised approximately HK$915 million (net proceeds of approximately HK$884 million) through the placement of new shares, with approximately 56.5% (approximately HK$500 million) explicitly designated for “expanding the product portfolio through investments and potential acquisitions in the medical device industry.”
 

In response, the industry anticipates that in 2026, INT Medical will accelerate its transformation from a “leader in vascular intervention” to a “comprehensive cardiovascular intervention solutions platform” through a series of moves, including financing and the strategic acquisition of equity in Valgen Holding Corporation.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.